Fresh Tracks Therapeutics, Inc. (FRTX)
Company Description
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States.
The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors.
Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.
Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Country | United States |
Founded | 2009 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Albert Nicholas Marchio II |
Contact Details
Address: 5777 Central Avenue, Suite 102 Boulder, Colorado 80301 United States | |
Phone | (720) 505-4755 |
Website | frtx.com |
Stock Details
Ticker Symbol | FRTX |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000819050 |
ISIN Number | AU000000ELD6 |
Employer ID | 93-0948554 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Albert Nicholas Marchio II | Chief Executive Officer, Chief Financial Officer, Secretary and Chairman |
Aron Aizenstat M.B.A., P.M.P. | Vice President of Corporate Development and Operations |
Sue Fattor | Head of Human Resource |
Dr. James S. McElvain Ph.D. | Interim Head of CMC Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2024 | 15-12G | Securities registration termination |
Mar 15, 2024 | 10-K | Annual Report |
Mar 7, 2024 | 8-K | Current Report |
Feb 16, 2024 | 8-K | Current Report |
Feb 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jan 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 17, 2024 | DEF 14A | Other definitive proxy statements |
Jan 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jan 5, 2024 | PRE 14A | Other preliminary proxy statements |
Jan 3, 2024 | 8-K | Current Report |